Efficacy News and Research

RSS
Novel strategy for neutralizing unwanted molecules and clearing them from the body

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Spectros introduces OnCall wireless remote access to view real-time patient results

Spectros introduces OnCall wireless remote access to view real-time patient results

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

FDA completes review of compounded hydroxyprogesterone caproate products and APIs

FDA completes review of compounded hydroxyprogesterone caproate products and APIs

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

Study reveals value of graphic warning labels on cigarette packaging

Study reveals value of graphic warning labels on cigarette packaging

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

Insulin more effective add-on than sitagliptin in glucose control

Insulin more effective add-on than sitagliptin in glucose control

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Positive top-line results from Teva’s GALA Phase III trial on RRMS

NIH awards $9 million grant to study aging and immunity to infections

NIH awards $9 million grant to study aging and immunity to infections

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures announces formation of Global Blood Therapeutics

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

MRF announces achievement of myelin repair Phase 1 trial for MS

MRF announces achievement of myelin repair Phase 1 trial for MS

Hay fever vaccine shows efficacy in phase IIa trial

Hay fever vaccine shows efficacy in phase IIa trial

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

AB Science announces results from masitinib phase 2 study on MS

AB Science announces results from masitinib phase 2 study on MS

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis announces publication of preclinical research with ADXS-PSA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.